A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Clinical trial NCT05119335 · TERMINATED
Trial details
- NCT number
- NCT05119335
- Sponsor
- NiKang Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-26
- Primary completion
- 2025-08-22
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.